Perfromance Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Perfromance Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$715K	Buy	1,601 +1	+0.1%	+$466	0.02%	99
2025 Q4	$725K	Sell	1,600 -5	-0.3%	-$2.15K	0.02%	96
2025 Q3	$629K	Buy	1,605 +5	+0.3%	+$2.09K	0.02%	101
2025 Q2	$712K	Sell	1,600 -3	-0.2%	-$1.38K	0.02%	86
2025 Q1	$777K	Hold	1,603	–	–	0.03%	70
2024 Q4	$646K	Sell	1,603 -13	-0.8%	-$6.03K	0.02%	84
2024 Q3	$752K	Buy	1,616 +16	+1%	+$7.69K	0.03%	78
2024 Q2	$750K	Hold	1,600	–	–	0.03%	65
2024 Q1	$669K	Hold	1,600	–	–	0.03%	79
2023 Q4	$651K	Hold	1,600	–	–	0.03%	85
2023 Q3	$556K	Hold	1,600	–	–	0.03%	97
2023 Q2	$557K	Buy	1,600 +400	+33%	+$135K	0.03%	104
2023 Q1	$378K	Buy	1,200 +400	+50%	+$120K	0.02%	132
2022 Q4	$231K	Buy	+800	New	+$244K	0.01%	149

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perfromance Wealth Partners's VRTX Position: Q1 2026 in Review

Perfromance Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 0.06% in Q1 2026, buying an estimated $466 and bringing the position to 1,601 shares worth $715K. The position accounts for 0.02% of the portfolio, ranked #99.

Perfromance Wealth Partners first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $777K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Perfromance Wealth Partners held 1,601 shares of Vertex Pharmaceuticals worth $715K as of Q1 2026.
Perfromance Wealth Partners bought 1 Vertex Pharmaceuticals share in Q1 2026, an estimated $466.
Vertex Pharmaceuticals made up 0.02% of Perfromance Wealth Partners's portfolio in Q1 2026, its #99 holding.
Perfromance Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
Perfromance Wealth Partners's Vertex Pharmaceuticals position peaked at $777K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Perfromance Wealth Partners's 13F filing for Q1 2026, filed 10 Apr 2026.